Can you take Mounjaro for life? What the evidence says about long-term use

What happens to weight when tirzepatide stops, and why that shapes the duration question

The SURMOUNT-4 trial was specifically designed to answer what happens after people stop tirzepatide. Participants who lost weight during an open-label lead-in phase were then randomised to continue or switch to placebo. Those who continued lost further weight; those who stopped regained around two-thirds of what they had lost within 52 weeks. The pattern echoes findings from GLP-1 trials more broadly: the medicine is working on biological pathways (appetite signalling, gastric emptying, hormonal feedback) that resume their previous state when treatment ends.

This does not mean everyone needs to take it forever. Some people use a defined course to reach a healthier weight, then sustain that through diet and activity changes. Others find that stopping leads to gradual regain and that the health benefits (lower blood pressure, improved blood sugar, reduced strain on joints) diminish with it. The decision belongs in a clinical conversation, not in a blanket rule. Our clinical team page has more on how prescribers at nume approach ongoing treatment decisions.

What the evidence does establish is that treating obesity as a temporary problem solved by a fixed course is not well-supported by the data if you are wondering whether you can be on Mounjaro for life. The biology that makes weight management difficult does not permanently reset.

What the UK licence and NICE guidance actually say about duration

The Mounjaro SmPC (the authoritative prescribing document) does not set a maximum treatment duration. It specifies the conditions under which treatment should be reviewed: if a patient does not achieve at least 5% weight loss after six months at the highest tolerated dose, continuing is not recommended. That is a performance threshold, not a calendar cutoff.

NICE's appraisal of tirzepatide, TA1026, reflects similar thinking. The recommendation supports use in adults with a BMI of 35 or above alongside at least one weight-related condition, with review at six months. Beyond that, the guidance is silent on duration, consistent with viewing obesity management as ongoing rather than episodic. For context on how that compares with semaglutide, which does carry a two-year cap under its NICE recommendation, our tirzepatide overview covers the distinction.

In practice, private prescribers follow the SmPC and clinical judgement. At every repeat, a clinician should be asking: is the patient still benefiting? Are side effects acceptable? Has anything changed in their health picture that alters the risk-benefit balance? At nume, a GPhC-registered prescriber reads every repeat request, not a queue, not a system check.

How long-term prescribing works in a regulated private setting

Long-term use of any prescription medicine requires structure. For Mounjaro that means regular reviews, honest reporting of side effects, and evidence of continued benefit. There is no subscription that ships pens automatically regardless of what is happening clinically. At nume, every repeat order is individually re-reviewed before anything is dispensed, a point worth understanding before choosing any provider.

For patients transferring from another service or requesting a dose increase, evidence of their current treatment is part of that review. The process for obtaining Mounjaro through a regulated UK pharmacy is built around these checks at every stage. It does mean an extra step each time, but that step is why the medicine you receive is genuine and the dose you are on is appropriate.

Practically speaking, long-term treatment tends to settle into a rhythm. Many people find that once they reach their maintenance dose the weekly injection becomes unremarkable, it fits around a Monday morning, or a payday week when the repeat order goes in. The clinical part is handled; the habit is the medicine.

One area that often comes up in longer-term prescribing: what happens to oral contraceptive absorption. For the first four weeks of treatment and after each dose increase, tirzepatide can reduce absorption of the pill, so an additional method is recommended during those windows. The weight-loss treatment overview covers this alongside other practical considerations. For cost and what is included at each stage, our treatment page has the detail.

Questions to bring to your prescriber about continuing treatment

If you are considering Mounjaro long-term (or are already on it and wondering whether to continue) the questions that matter clinically are fairly concrete. Is your weight still stable or trending in the right direction? Are side effects manageable? Have your blood pressure, blood sugar, or other relevant markers changed? Do you have upcoming surgery, a planned pregnancy, or any new medicines that might interact? Pregnancy is a particular consideration: Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive, so contraceptive planning is part of the longer-term picture, especially for those considering Mounjaro for life.

The nume FAQ section covers some of the most common questions about ongoing treatment. For specific questions about your situation, the right place is a conversation with a prescriber rather than a general page. Related topics on duration (including whether staying on Mounjaro is obligatory and what it means in practice if you can stay on Mounjaro for life) are worth reading alongside this one.

If you would like a prescriber to assess whether starting or continuing treatment is appropriate for you, you can speak to our prescribers through a free consultation, reviewed the same day, no waiting list.